Dexcom Inc ($DXCM) Q4 2024 Earnings Call
... like to welcome everyone to the Dexcom Inc fourth quarter 2024 earnings release conference call All lines have been placed on ...
Executive Chairman, Dexcom
Search every verified Kevin Sayer interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Kevin Sayer, chairman, president, and CEO of Dexcom, discussed the company's fourth quarter and full-year 2024 results during a January 30, 2025 earnings call. He reported that Dexcom ended 2024 with more than 2.8 million global customers on its G series and D series products, a roughly 25% increase from 2023. Sayer also stated that as of January 2025, two of the three largest pharmacy benefit managers (PBMs) cover Dexcom continuous glucose monitors (CGM) for anyone with diabetes, and he projected that national formularies would lead to coverage for over 5 million people with type 2 diabetes not on insulin in the U.S., which he noted is larger than the type 2 basal reimbursement that occurred less than two years prior. During the call's Q&A session, Sayer addressed questions about PBM coverage and economics, saying that per-transaction economics do not change with expanded coverage, though utilization may increase. He also mentioned ongoing work with a third PBM and with CMS to expand access, and noted that Dexcom is running a randomized controlled trial (RCT) with enrollment expected to complete in the first half of 2025 and early readouts later in the year. In closing remarks, Sayer expressed satisfaction with 2024 results, citing record new patients, and said the company has "many levers" in place for a strong 2025.
... like to welcome everyone to the Dexcom Inc fourth quarter 2024 earnings release conference call All lines have been placed on ...
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom ...
Dexcom's stock dropped when GLP-1s hit the scene—so they decided to embrace the disruption. CEO Kevin Sayer explains why ...
This week, Dexcom CEO Kevin Sayer talks to us about building a $33B digital health juggernaut. We get a sneak peek at the ...
Dexcom generates more than $4 billion in annual revenue and has a market cap north of $30 billion, making it one of the biggest ...
This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company – and the industry group AdvaMed – has been working to increase diversity of its workforce, particularly in senior and sales positions. Lobo is serving a two-year term as chairman of AdvaMed. In this interview, Lobo speaks specifically to how Stryker is tracking progress, where it has come up short, and how it’s working to help workers identify their own biases. Lobo a…
In this week’s episode, CEO Kevin Sayer takes a few minutes to share Dexcom’s vision for the future OUTSIDE of diabetes. What does this mean for people with diabetes and others who could benefit from the powerful Dexcom G7? We also bring in a very popular interview from our MedtronicTalks podcast series – Skip Kiil, president of cranial and spinal technologies, shares some very wise career advice that helped him accelerate his career. He also talks with Tom Salemi about his move to Medtronic and how the company is ramping up to dominate the spinal and cranial spaces. His interview is sponsored…
Stacey sits down with Dexcom’s CEO for an in-person interview at ADA Scientific Sessions. Dexcom made a little bit of news at the conference, but it’s a less-trumpeted replacement policy that had you all asking a lot of questions. We’ll go through the latest news, updates, sensor issues, and a peek into the future with Dexcom’s CEO Kevin Sayer. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors…
Join our Newsletter: https://bit.ly/diabetechnews Follow me here: / diabe_tech / diabe_tech / diabetechjustin / discord 🎧 Listen to the podcast: https://www.diabetechpodcast.com T1D Exchange Registry Signup (US only): https://bit.ly/t1dregistry Support us on Patreon (extra content): https://bit.ly/3TKpdRK Diabetech Community Discord: / discord CEO Kevin Sayer explains Dexcom's has a new sensor policy, and explains G7 range and reconnect upgrades. I ask him about what the future of Dexcom sensors look like from the G8 to non-invasive tech. Follow our Youtube and social…
Ep. 166: Basketball shaped the CEO at the helm of the global leader in real-time continuous glucose monitoring for people with diabetes. Kevin’s days coaching have taught him the value of teamwork– lessons he applies to his 8,300 Dexcom employees that go to work to accomplish the mission of empowering people to take control of their health. Our BONUS RESOURCE for this episode includes fill-in-the-blank notes and reflection questions. Click here to download the bonus resource. Looking for a speaker for your next event? From more than 30 years of interviewing and studying the greatest wi…
Sign in to search the full transcript archive, filter by topic, and access every quote from Kevin Sayer.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans